tradingkey.logo

Treace Medical Concepts Inc <TMCI.OQ> expected to post a loss of 4 cents a share - Earnings Preview

ReutersFeb 25, 2025 10:01 PM
  • Treace Medical Concepts Inc TMCI.OQ TMCI.O is expected to show a rise in quarterly revenue when it reports results on February 27 for the period ending December 31 2024

  • The Ponte Vedra Florida-based company is expected to report a 7.9% increase in revenue to $67.157 million from $62.21 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on January 13 2025, for the period ended December 31, was for revenue between $68.40 million and $68.80 million.

  • ​LSEG's mean analyst estimate for Treace Medical Concepts Inc is for a loss of 4 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Treace Medical Concepts Inc is $8.20​, below​ its last closing price of $9.59. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.27

-0.27

-0.25

Beat

8

Jun. 30 2024

-0.29

-0.29

-0.29

Met

0

Mar. 31 2024

-0.30

-0.30

-0.30

Met

0.9​

Dec. 31 2023

-0.09

-0.09

-0.10

Missed

-12.9

​​Sep. 30 2023

-0.25

-0.26

-0.28

Missed

-7.1

Jun. 30 2023

-0.23

-0.24

-0.20

Beat

16.1​

Mar. 31 2023

-0.23

-0.23

-0.23

Met

-0.7

Dec. 31 2022

-0.15

-0.14

-0.08

Beat

42.9

This summary was machine generated February 25 at 22:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI